NO20063801L - Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse - Google Patents

Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse

Info

Publication number: NO20063801L
Authority: NO; Norway
Prior art keywords: agonists; vpac2; receptor; pacap; pituitary
Prior art date: 2004-01-27

Application number

NO20063801A

Other languages

English (en)

Norwegian (no)

Inventor

Kevin Clairmont

Kevin J Lumb

Thomas Buckholz

Arthur I Salhanick

Original Assignee

Bayer Pharmaceuticals Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-27

Filing date

2006-08-25

Publication date

2006-10-26

2006-08-25 Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp

2006-10-26 Publication of NO20063801L publication Critical patent/NO20063801L/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 title abstract 2
239000000556 agonist Substances 0.000 title abstract 2
101000666868 Homo sapiens Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 title 1
230000000144 pharmacologic effect Effects 0.000 title 1
102000005962 receptors Human genes 0.000 title 1
108020003175 receptors Proteins 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 2
239000008103 glucose Substances 0.000 abstract 2
238000001727 in vivo Methods 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
229920001184 polypeptide Polymers 0.000 abstract 2
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
208000016097 disease of metabolism Diseases 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
230000001771 impaired effect Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
208000030159 metabolic disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000003248 secreting effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Hematology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Zoology (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)

NO20063801A 2004-01-27 2006-08-25 Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse NO20063801L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US53955004P	2004-01-27	2004-01-27
US56649904P	2004-04-29	2004-04-29
PCT/US2005/002609 WO2005072385A2 (en)	2004-01-27	2005-01-27	Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use

Publications (1)

Publication Number	Publication Date
NO20063801L true NO20063801L (no)	2006-10-26

Family

ID=34830483

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20063801A NO20063801L (no)	2004-01-27	2006-08-25	Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse

Country Status (13)

Country	Link
US (1)	US20090143283A1 (pt)
EP (1)	EP1713493A4 (pt)
JP (1)	JP2007519739A (pt)
KR (1)	KR20070009554A (pt)
AU (1)	AU2005208911A1 (pt)
BR (1)	BRPI0507177A (pt)
CA (1)	CA2554475A1 (pt)
EC (1)	ECSP066793A (pt)
IL (1)	IL176705A0 (pt)
MA (1)	MA28335A1 (pt)
NO (1)	NO20063801L (pt)
RU (1)	RU2006130691A (pt)
WO (1)	WO2005072385A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1768686A4 (en) *	2004-06-12	2007-11-14	Bayer Pharmaceuticals Corp	PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE
EP1896048A4 (en) *	2005-05-06	2010-11-03	Bayer Pharmaceuticals Corp	PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE
US7582608B2 (en)	2005-10-26	2009-09-01	Eli Lilly And Company	Selective VPAC2 receptor peptide agonists
US9782454B2 (en)	2010-04-22	2017-10-10	Longevity Biotech, Inc.	Highly active polypeptides and methods of making and using the same
US9789164B2 (en)	2013-03-15	2017-10-17	Longevity Biotech, Inc.	Peptides comprising non-natural amino acids and methods of making and using the same
TWI721976B (zh)	2015-04-16	2021-03-21	美商艾爾德生物製藥股份有限公司	抗ｐａｃａｐ抗體及其用途
EP3426288A4 (en)	2016-04-15	2019-10-30	Alder Biopharmaceuticals, Inc.	ANTI-PACAP ANTIBODIES AND USES THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU656230B2 (en) *	1991-10-11	1995-01-27	F. Hoffmann-La Roche Ag	Cyclic vasoactive peptides
RU2269354C2 (ru) *	1999-09-28	2006-02-10	Байер Корпорейшн	Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения
WO2003068805A2 (en) *	2002-02-14	2003-08-21	Bayer Pharmaceuticals Corporation	Formulation strategies in stabilizing peptides in organic solvents and in dried states
JP2006506969A (ja) *	2002-07-12	2006-03-02	バイエル・フアーマシユーチカルズ・コーポレーシヨン	下垂体アデニル酸シクラーゼ活性化ペプチド（ｐａｃａｐ）受容体（ｖｐａｃ２）アゴニストおよびそれらの薬理学的使用方法

2005
- 2005-01-27 EP EP05712166A patent/EP1713493A4/en not_active Withdrawn
- 2005-01-27 RU RU2006130691/15A patent/RU2006130691A/ru not_active Application Discontinuation
- 2005-01-27 AU AU2005208911A patent/AU2005208911A1/en not_active Abandoned
- 2005-01-27 KR KR1020067015124A patent/KR20070009554A/ko not_active Withdrawn
- 2005-01-27 CA CA002554475A patent/CA2554475A1/en not_active Abandoned
- 2005-01-27 JP JP2006551478A patent/JP2007519739A/ja active Pending
- 2005-01-27 BR BRPI0507177-1A patent/BRPI0507177A/pt not_active IP Right Cessation
- 2005-01-27 WO PCT/US2005/002609 patent/WO2005072385A2/en not_active Ceased
- 2005-01-27 US US10/586,124 patent/US20090143283A1/en not_active Abandoned
2006
- 2006-07-04 IL IL176705A patent/IL176705A0/en unknown
- 2006-07-24 MA MA29206A patent/MA28335A1/fr unknown
- 2006-08-25 NO NO20063801A patent/NO20063801L/no not_active Application Discontinuation
- 2006-08-25 EC EC2006006793A patent/ECSP066793A/es unknown

Also Published As

Publication number	Publication date
WO2005072385A3 (en)	2006-06-08
KR20070009554A (ko)	2007-01-18
RU2006130691A (ru)	2008-03-10
EP1713493A4 (en)	2009-06-24
AU2005208911A1 (en)	2005-08-11
WO2005072385A2 (en)	2005-08-11
IL176705A0 (en)	2006-10-31
JP2007519739A (ja)	2007-07-19
US20090143283A1 (en)	2009-06-04
ECSP066793A (pt)	2006-11-16
BRPI0507177A (pt)	2007-06-26
MA28335A1 (fr)	2006-12-01
CA2554475A1 (en)	2005-08-11
EP1713493A2 (en)	2006-10-25

Similar Documents

Publication	Publication Date	Title
Lieblich et al.	2017	4 S-Hydroxylation of insulin at ProB28 accelerates hexamer dissociation and delays fibrillation
ES2307619T3 (es)	2008-12-01	Tratamiento del sindrome coronario agudo con glp-1.
NO20070614L (no)	2007-03-27	Humane glukagon-lignende-peptid-1 modulatorer og anvendelse derav ved behandling av diabetes og beslektede tilstander.
ES2549955T3 (es)	2015-11-03	Prevención de hipoglucemia en pacientes con diabetes mellitus de tipo 2
CN104144704B (zh)	2018-03-23	Glp‑1受体激动剂肽胃泌素缀合物
WO2006121860A3 (en)	2007-04-12	Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
NO20055129L (no)	2006-01-23	Fenylsubstituerte karboksylsyrer
NO20082958L (no)	2008-08-26	Humane glukagon-lignende-peptid-1 modulatorer og anvendelse derav for behandling av diabetes og beslektede tilstander
DOP2003000669A (es)	2004-01-31	Agonistas del receptor (vpac2) del peptido activante de la adelinato ciclasa hipofisaria (pacap) y sus metodos de uso farmacológicos
WO2007140284A3 (en)	2008-12-31	N-terminally modified glp-1 receptor modulators
BRPI0418702A (pt)	2007-09-11	composição para a liberação sustentada de polipetìdeo biologicamente ativo, método para tratar um paciente sofrendo de diabetes tipo 2, processo para preparar uma composição para a liberação sustentada de um polipeptìdeo, composição para a liberação sustentada de um agente biologicamente ativo, processo para preparar uma composição para a liberação sustentada de exendina-4, composição injetável, kit para produzir uma composição injetável, composição farmaceuticamente aceitável para a liberação sustentada de um polipeptìdeo biologicamente ativo e método para tratar um paciente sofrendo de diabetes mellitus
ATE482717T1 (de)	2010-10-15	Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten
EA200900896A1 (ru)	2010-04-30	Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
NO20054769L (no)	2006-01-03	Substituerte fenylalkansyrer
NO20054958L (no)	2006-01-23	Substitulerte aminokarboksylsyrer
US20200176101A1 (en)	2020-06-04	Methods and medical uses relating to the treatment of hypoglycaemia
NO20063801L (no)	2006-10-26	Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse
Yoo et al.	2006	Formulary forum: Exenatide: A new option for the treatment of type 2 diabetes
BR0306798A (pt)	2004-12-07	Uso de melagatran ou de um derivado farmaceuticamente aceitável deste, métodos de tratamento de diabetes mellitus tipo i, de transplante de células de enxertamento de ilhotas de langerhans, para melhorar a independência de insulina em pacientes com diabetes mellitus tipo i, e de tratamento de reação inflamatória mediada pelo sangue instantânea, formulação farmacêutica para uso no tratamento de diabetes mellitus tipo i, kit de partes, e, método de fabricação de um kit de partes.
Riddle	2006	The Treat-to-Target Trial and related studies
Abdi et al.	2023	Effects of incretin pathway elements on bone properties
EA200600402A1 (ru)	2006-08-25	Клеточные стенки дрожжей для лечения или профилактики гипергликемии или для стабилизации уровня сахара в крови
WO2011128782A3 (en)	2012-01-19	Compositions and methods for treating type ii diabetes and related disorders
Mest	2006	Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement
Ma et al.	2009	Poly‐GLP‐1, a novel long‐lasting glucagon‐like peptide‐1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta‐cell proliferation

Legal Events

Date	Code	Title	Description
2010-08-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application